Home Cart Sign in  
Chemical Structure| 75438-57-2 Chemical Structure| 75438-57-2

Structure of Moxonidine
CAS No.: 75438-57-2

Chemical Structure| 75438-57-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Moxonidine is a selective agonist of imidazoline I1 receptors and alpha-2 receptor used as an antihypertensive drug.

Synonyms: BDF5895; LY326869

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Moxonidine

CAS No. :75438-57-2
Formula : C9H12ClN5O
M.W : 241.68
SMILES Code : CC1=NC(OC)=C(NC2=NCCN2)C(Cl)=N1
Synonyms :
BDF5895; LY326869
InChI Key :WPNJAUFVNXKLIM-UHFFFAOYSA-N
Pubchem ID :4810

Safety of Moxonidine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02614794 HER2 Positive Breast Cancer Phase 2 Recruiting July 2021 -
NCT03622905 Alzheimer Disease Not Applicable Not yet recruiting October 1, 2024 -
NCT02574455 Breast Cancer Phase 3 Recruiting June 2020 -
NCT00424801 Microvascular Angina ... More >> Hypertension Less << Not Applicable Terminated(Due to recent findi... More >>ngs relating MRI contrast to nephrogenic systemic fibrosis) Less << December 2008 Denmark ... More >> Aarhus Hospital Aarhus, Denmark, 8000 Less <<
NCT02734290 Triple Negative Breast Cancer Phase 1 Phase 2 Recruiting May 2022 United States, Oregon ... More >> Providence Cancer Center Recruiting Portland, Oregon, United States, 97213 Contact: Nikki Moxon, RN    503-215-2619    nicole.moxon@providence.org    Contact: Brenda Fisher, RN    503-215-2613    brenda.fisher@providence.org    Sub-Investigator: Walter J. Urba, M.D., Ph.D          Sub-Investigator: Rachel Sanborn, MD          Sub-Investigator: Todd Crocenzi, MD          Sub-Investigator: Rui Li, MD, PhD          Sub-Investigator: Rom Leidner, MD          Sub-Investigator: Brendan Curti, MD          Sub-Investigator: Alison Conlin, MD          Sub-Investigator: John Godwin, MD          Principal Investigator: David Page, MD          Sub-Investigator: Anupama Acheson, MD          Sub-Investigator: Nicholas Barber, MD          Sub-Investigator: Regan Duffy, MD          Sub-Investigator: Stacy Lewis, MD          Sub-Investigator: Christine Lin, MD          Sub-Investigator: Christie Moore, DO Less <<
NCT00518479 Hypertension ... More >>Left Ventricular Hypertrophy Less << Not Applicable Completed - United Kingdom ... More >> Leeds Teaching Hospital NHS Trust Leeds, Wesst Yorkshire, United Kingdom, LS1 3EX Less <<
NCT03650894 Breast Neoplasm Female ... More >> Breast Cancer Breast Carcinoma Breast Tumor Less << Phase 2 Not yet recruiting October 2023 United States, Oregon ... More >> Providence Oncology & Hematology Care Clinic - Eastside Not yet recruiting Portland, Oregon, United States, 97213 Sub-Investigator: Rachel Sanborn, MD          Sub-Investigator: Alison Conlin, MD          Sub-Investigator: Todd Crocenzi, MD          Sub-Investigator: Brendan Curti, MD          Sub-Investigator: John Godwin, MD          Sub-Investigator: Rom Leidner, MD          Sub-Investigator: Rui Li, MD, PhD          Sub-Investigator: Walter Urba, MD, PhD          Principal Investigator: David Page, MD          Sub-Investigator: Herschel Wallen, MD          Sub-Investigator: Moran Amy, PhD Less <<
NCT01138423 Hypertension ... More >>Abdominal Obesity Metabolic Syndrome Less << Phase 4 Completed - Netherlands ... More >> UMC Utrecht Utrecht, Netherlands, 3508 GA Less <<
NCT01504321 Polycystic Ovary Syndrome Phase 4 Completed - Australia, Victoria ... More >> Heart Centre, Alfred Hospital Prahran, Victoria, Australia, 3004 Less <<
NCT01567124 Schizophrenia Phase 4 Unknown December 2014 Australia, Victoria ... More >> Ballarat Health Service Psychiatric Services Recruiting Ballarat, Victoria, Australia Principal Investigator: Abdul Khalid          Sub-Investigator: Rajul Tandon          Sub-Investigator: Sonia Ghai          Sub-Investigator: Arup Dhar          Sub-Investigator: Sarah Tremethick          Sub-Investigator: Jennifer Grigo          Sub-Investigator: Pella Karalis          Monash Medical Centre - Monash Health Recruiting Clayton, Victoria, Australia Principal Investigator: David Barton          Sub-Investigator: Arup Dhar          Sub-Investigator: Sarah Tremethick          Sub-Investigator: Jennifer Grigo          Sub-Investigator: Krishna Vaddadi          Alfred and Baker Medical Unit - Alfred Hospital Recruiting Melbourne, Victoria, Australia Principal Investigator: Gavin Lambert          Sub-Investigator: Markus Schlaich          Sub-Investigator: Elisabeth Lambert          Sub-Investigator: Murray Esler          Sub-Investigator: Geoff Head          Sub-Investigator: Dagmara Hering          Sub-Investigator: Nina Eikelis          Sub-Investigator: Carolina Ika Sari          Sub-Investigator: Petra Marusic          Sub-Investigator: Toni Rice          Sub-Investigator: Mariee Grima          Sub-Investigator: David Barton          Sub-Investigator: Arup Dhar          Sub-Investigator: Sarah Tremethick          Sub-Investigator: Nora Straznicky          Sub-Investigator: John Dixon          Sub-Investigator: Jennifer Grigo          Sub-Investigator: Donna Vizi          Sub-Investigator: Louise Hammond          Baker IDI Heart & Diabetes Institute Recruiting Melbourne, Victoria, Australia Principal Investigator: Gavin Lambert          Sub-Investigator: Markus Schlaich          Sub-Investigator: Elisabeth Lambert          Sub-Investigator: Murray Esler          Sub-Investigator: Geoff Head          Sub-Investigator: Dagmara Hering          Sub-Investigator: Nina Eikelis          Sub-Investigator: Carolina Ika Sari          Sub-Investigator: Petra Marusic          Sub-Investigator: Toni Rice          Sub-Investigator: Mariee Grima          Sub-Investigator: David Barton          Sub-Investigator: Arup Dhar          Sub-Investigator: Sarah Tremethick          Sub-Investigator: Nora Straznicky          Sub-Investigator: John Dixon          Sub-Investigator: Jennifer Grigo          Sub-Investigator: Donna Vizi          Sub-Investigator: Louise Hammond Less <<
NCT03289364 Breast Cancer Not Applicable Recruiting July 1, 2020 United States, Oregon ... More >> Providence Cancer Center Recruiting Portland, Oregon, United States, 97213 Contact: Nikki Moxon, RN    503-215-2619    nicole.moxon@providence.org    Contact: Brenda Fisher, RN    503-215-2613    brenda.fisher@providence.org    Sub-Investigator: Walter J. Urba, M.D., Ph.D          Sub-Investigator: Rachel Sanborn, MD          Sub-Investigator: Todd Crocenzi, MD          Sub-Investigator: Rui Li, MD, PhD          Sub-Investigator: Rom Leidner, MD          Sub-Investigator: Brendan Curti, MD          Sub-Investigator: Alison Conlin, MD          Sub-Investigator: John Godwin, MD          Principal Investigator: David Page, MD          Sub-Investigator: Anupama Acheson, MD          Sub-Investigator: Nicholas Barber, MD          Sub-Investigator: Regan Duffy, MD          Sub-Investigator: Stacy Lewis, MD          Sub-Investigator: Christine Lin, MD          Sub-Investigator: Christie Moore, DO          Sub-Investigator: Herschel Wallen, MD Less <<
NCT01791699 Atrial Fibrillation Phase 4 Completed - Greece ... More >> Evangelismos General Hospital Athens, Greece, 10676 Athens General Hospital "G. Gennimatas" Athens, Greece, 11527 Red Cross Hospital Athens, Greece Less <<
NCT00160160 Hypertension ... More >>Type 2 Diabetes Less << Not Applicable Completed - -
NCT01094769 Diabetic Nephropathies Phase 4 Unknown April 2015 Australia, Victoria ... More >> Alfred & Baker Medical Unit Recruiting Melbourne, Victoria, Australia Principal Investigator: Markus P Schlaich, MD          Principal Investigator: Gavin W Lambert, BSc PhD Less <<
NCT01180231 Obesity Overw... More >>eight Less << Phase 4 Unknown September 2014 Australia, Victoria ... More >> BakerIDI Heart and Diabetes Institute Not yet recruiting Prahran, Victoria, Australia, 3004 Contact: Elisabeth Lambert, PhD    03 8532 1345    elisabeth.lambert@bakeridi.edu.au    BakerIDI Heart and Diabetes Institute Recruiting Prahran, Victoria, Australia, 3004 Contact: Carolina Sari, BSci (Hons.)    03 8532 1163    carolina.ikasari@bakeridi.edu.au Less <<
NCT00244504 Cardiac Disease ... More >> Vascular Surgery Less << Phase 3 Terminated(Study was stopped a... More >>fter pre-definied interim analysis because of no effects) Less << - Switzerland ... More >> University hospital Basel, CH, Switzerland, 4000 Less <<
NCT02355821 Osteopenia Ar... More >>terial Hypertension Less << Not Applicable Completed - Russian Federation ... More >> National Research Center for Preventive Medicine Moscow, Russian Federation, 101000 Less <<
NCT00160277 Hypertension PHASE3 COMPLETED - Site 1, Jubillee Hills Hyderab... More >>ad, India|Site 2, Mangalore, India|Site 3, New Delhi, India Less <<
NCT01360710 Abdominal Obesity ... More >> Hypertension Less << Phase 4 Unknown - Australia, Victoria ... More >> BakerIDI Heart and Diabetes Institute Recruiting Prahran, Victoria, Australia, 3004 Contact: Markus Schlaich       markus.schlaich@bakeridi.edu.au Less <<
NCT05147753 Obesity|Hypertension PHASE4 COMPLETED 2014-06-30 -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.14mL

0.83mL

0.41mL

20.69mL

4.14mL

2.07mL

41.38mL

8.28mL

4.14mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories